NASDAQ:CARA
Cara Therapeutics Stock News
$0.716
-0.0445 (-5.85%)
At Close: May 10, 2024
Cantor Fitzgerald Reiterates Overweight on Cara Therapeutics, Raises Price Target to $40
11:27am, Tuesday, 19'th May 2020Cannabis Central: Pot Stock Index Up 4.8% Last Week; Cultivation/Retail Category Up 10.8%
12:00am, Sunday, 17'th May 2020Government launches 'Return to Sport Expert Group' amid Covid-19 pandemic
04:12pm, Saturday, 16'th May 2020
The group will aim to coordinate a safe return to sport over the coming months
Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now?
03:00pm, Friday, 15'th May 2020
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
12:00am, Wednesday, 13'th May 2020
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and aut
Edited Transcript of CARA earnings conference call or presentation 11-May-20 8:30pm GMT
01:30pm, Tuesday, 12'th May 2020
Q1 2020 Cara Therapeutics Inc Earnings Call
Cara Therapeutics Inc (CARA) Q1 2020 Earnings Call Transcript
10:00am, Tuesday, 12'th May 2020
This is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics' first quarter 2020 financial results and update conference call. Before we begin, let me remind you that sta
Shilpa Shetty On Miscarriages, Surrogacy And Motherhood
05:21am, Tuesday, 12'th May 2020
"We had Samisha after three attempts. I had honestly given up on the thought of another child," said Shilpa Shetty
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2020 Results - Earnings Call Transcript
05:06am, Tuesday, 12'th May 2020
Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jack Hildick-Smith - Stern Investor Relation
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Monday, 11'th May 2020
Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics Q1 EPS $(0.620), Inline, Sales $8.093M Beat $4.760M Estimate
08:06pm, Monday, 11'th May 2020Cara Therapeutics Reports First Quarter 2020 Financial Results
08:01pm, Monday, 11'th May 2020
STAMFORD, Conn., May 11, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
